Company / Free Cash Flow per Share
Neurocrine Biosciences Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
$7.53
FY2025
5-year range
$2.49 / $7.53
FY2021-FY2025
Trend
+33.4%
vs FY2024
Sector context
#14 of 190
Health Care
What the data says
Among 190 Health Care companies, Neurocrine Biosciences is in the top 7% for free cash flow per share. Free Cash Flow per Share has increased for 9 consecutive years, from $-1.28 in FY2016 to $7.53 in FY2025.
Based on SEC 10-K filings.
7.53 in FY2025 with a 5-year CAGR of +26.2%. Top quartile in the Health Care sector.
Improved from $3.75 to $7.53 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +30.3%
- 5-Year CAGR
- +26.2%
- 10-Year CAGR
- -
Sector benchmark
+126.5% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's free cash flow per share has grown for 9 consecutive years.
- In FY2025, free cash flow per share increased 33.4% year-over-year.
- Ranks #14 out of 190 companies in the Health Care sector.
- Lowest free cash flow per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.53 | +33.4% |
| FY2024 | $5.65 | +50.7% |
| FY2023 | $3.75 | +10.1% |
| FY2022 | $3.40 | +36.5% |
| FY2021 | $2.49 | +5.7% |
| FY2020 | $2.36 | +61.8% |
| FY2019 | $1.46 | +68.9% |
| FY2018 | $0.86 | +174.0% |
| FY2017 | -$1.17 | +8.8% |
| FY2016 | -$1.28 | -144.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026